The fate of platinum(II) and platinum(IV) anti-cancer agents in cancer cells and tumours

Journal of Structural Biology

Volumn 155, Issue 1, 2006, Pages 38-44

  Hall, Matthew D ^a   Alderden, Rebecca A ^a   Zhang, Mei ^b   Beale, Philip J ^b   Cai, Zhonghou ^c   Lai, Barry ^c   Stampfl, Anton P J ^c,d   Hambley, Trevor W ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c ARGONNE NATIONAL LABORATORY   (United States)

^d AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION   (Australia)

Author keywords

Cancer cells; Platinum; Reduction; Reductive activation; SRIXE

Indexed keywords

ANTINEOPLASTIC AGENT; BROMINE; PLATINUM DERIVATIVE;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL NUCLEUS; CONTROLLED STUDY; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG UPTAKE; HUMAN; HUMAN CELL; OVARY CELL CULTURE; PRIORITY JOURNAL; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BROMINE COMPOUNDS; ELECTRON PROBE MICROANALYSIS; FEMALE; HUMANS; INTERCALATING AGENTS; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED BALB C; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33744986491     PISSN: 10478477     EISSN: 10958657     Source Type: Journal    
DOI: 10.1016/j.jsb.2006.01.011     Document Type: Article

References (14)

1. Alderden, R.A., 2005. PhD Thesis. School of Chemistry; University of Sydney: Sydney.
2. Carmichael J., DeGraff W.G., Gazdar A.F., Minna J.D., and Mitchell J.B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Canc. Res. 47 (1987) 936-942
3. Dillon C.T., Lay P.A., Kennedy B.J., Stampfl A.P.J., Cai Z., Ilinski P., Rodrigues W., Legnini D.G., Lai B., and Maser J. Hard X-ray microprobe studies of chromium(VI)-treated V79 Chinese hamster lung cells: intracellular mapping of the biotransformation products of a chromium carcinogen. J. Biol. Inorg. Chem. 7 (2002) 640-645
4. Dolman R., Hambley T.W., and Deacon G.B. Studies of the binding of a series of platinum(IV) complexes to plasma proteins. J. Inorg. Biochem. 88 (2002) 260-267
5. Hall, M.D. 2004. PhD Thesis. School of Chemistry; University of Sydney: Sydney.
6. Hall M.D., Dillon C.T., Zhang M., Beale P., Cai Z., Lai B., Stampfl A.P.J., and Hambley T.W. The cellular distribution and oxidation state of platinum(II) and platinum(IV) antitumour complexes in cancer cells. J. Biol. Inorg. Chem. 8 (2003) 726-732
7. Hall M.D., Foran G.J., Zhang M., Beale P., and Hambley T.W. XANES Determination Of The Platinum Oxidation State Distribution In Cancer Cells Treated With Platinum(IV) Anticancer Agents. J. Am. Chem. Soc. 125 (2003) 7524-7525
8. Hall M.D., Martin C., Ferguson D.J.P., Phillips R.M., Hambley T.W., and Callaghan R. Comparative efficacy of novel platinum(IV) compounds with established chemotherapeutic drugs in solid tumour models. Biochem. Pharmacol. 67 (2004) 17-30
9. Hambley T.W. The Influence of Structure on the Activity and Toxicity of Pt Anticancer Drugs. Coord. Chem. Rev. 166 (1997) 181-223
10. Hambley T.W., Battle A.R., Deacon G.B., Lawrenz E.T., Fallon G.D., Gatehouse B.M., Webster L.K., and Rainone S. Modifying the properties of platinum(IV) complexes in order to increase biological effectiveness. J. Inorg. Biochem. 77 (1999) 3-12
11. Hambley, T.W., Foran, G.J., Hall, M.D., 2002. XANES Determination of oxidation state in solutions of cobalt(II) and cobalt(III). unpublished data.
12. Holford J., Sharp S.Y., Murrer B.A., Abrams M., and Kelland L.R. In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473. Br. J. Cancer 77 (1998) 366-373
13. Mellor H.R., Snelling S., Hall M.D., Modok S., Jaffar M., Hambley T.W., and Callaghan R. The influence of tumour microenvironmental factors on the efficacy of cisplatin and novel platinum(IV) complexes. Biochem. Pharmacol. 70 (2005) 1137-1146
14. Siafaca, K. Oncology Trends Product Markets-Part I. In Future Oncology, 1999; pp. 1045-1071.